These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. Barkas F; Elisaf M; Liberopoulos E; Liamis G; Ntzani EE; Rizos EC J Cardiol; 2019 Sep; 74(3):290-295. PubMed ID: 30910387 [TBL] [Abstract][Full Text] [Related]
8. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. Sukhija R; Prayaga S; Marashdeh M; Bursac Z; Kakar P; Bansal D; Sachdeva R; Kesan SH; Mehta JL J Investig Med; 2009 Mar; 57(3):495-9. PubMed ID: 19188844 [TBL] [Abstract][Full Text] [Related]
9. Drug therapy of diabetic dyslipidemia: do the statins suffice? Mooradian AD Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161 [No Abstract] [Full Text] [Related]
10. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance. Brinton EA Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723 [TBL] [Abstract][Full Text] [Related]
11. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS. Parhofer KG Rev Invest Clin; 2018; 70(5):237-243. PubMed ID: 30307445 [TBL] [Abstract][Full Text] [Related]
12. Special issue on diabetes. Introduction. Brunton SA J Fam Pract; 2010 May; 59(5 Suppl):S2. PubMed ID: 20549884 [No Abstract] [Full Text] [Related]
14. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951 [No Abstract] [Full Text] [Related]
15. The role of dyslipidemia in diabetic retinopathy: a brighter focus? Jialal I; Rajamani U; Siegel D J Diabetes Complications; 2014; 28(6):753-4. PubMed ID: 25104239 [No Abstract] [Full Text] [Related]
16. Diabetes and dyslipidaemia. Kalra S; Unnikrishnan AG J Pak Med Assoc; 2013 Jun; 63(6):788-91. PubMed ID: 23901690 [TBL] [Abstract][Full Text] [Related]
17. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients. Choe EY; Wang HJ; Kwon O; Cho Y; Huh KH; Kim MS; Kim YS; Ahn CW; Cha BS; Lee HC; Kang ES Transplantation; 2014 Feb; 97(4):419-25. PubMed ID: 24285338 [TBL] [Abstract][Full Text] [Related]
18. Fibrates in the treatment of dyslipidemias--time for a reassessment. Goldfine AB; Kaul S; Hiatt WR N Engl J Med; 2011 Aug; 365(6):481-4. PubMed ID: 21830963 [No Abstract] [Full Text] [Related]
19. Statin related memory dysfunction in a Nigerian woman: a case report. Okeahialam BN; Isiguzoro I Curr Drug Saf; 2012 Feb; 7(1):33-4. PubMed ID: 22663955 [TBL] [Abstract][Full Text] [Related]
20. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Kim J; Lee HS; Lee KY Cardiovasc Diabetol; 2018 Dec; 17(1):155. PubMed ID: 30518364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]